Close Menu

This story has been updated to include information from Twist's Q3 investor call.

NEW YORK – Twist Bioscience reported a 56 percent increase in third quarter fiscal year 2020 revenues after the close of the market on Thursday.

For the quarter ended June 30, 2020, Twist reported $21.2 million in revenues, up from $13.6 million during the same period last year, beating Wall Street analysts' average revenue estimate of $14.2 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.